BIOPHYTIS SA (BPTSY) Financials
Newest figures come from the 10-K for FY2023, filed Apr 8, 2024. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BPTSY SEC filings page.
This page shows BIOPHYTIS SA (BPTSY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
BIOPHYTIS SA does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
BIOPHYTIS SA passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
BIOPHYTIS SA reported a net loss of $18.8M while operations used $14.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
BIOPHYTIS SA reported an operating loss of $15.9M against $1.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
BIOPHYTIS SA's EBITDA was -$15.0M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.
BIOPHYTIS SA reported a net loss of $18.8M in fiscal year 2023. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2023.
Cash & Balance Sheet
BIOPHYTIS SA held $6.2M in cash against $3.6M in long-term debt as of fiscal year 2023.
Not reported for fiscal year 2023.
Not reported for fiscal year 2023.
Margins & Returns
None of these metrics is reported for fiscal year 2023.
Capital Allocation
BIOPHYTIS SA invested $9.8M in research and development in fiscal year 2023. This represents a decrease of 43.0% from the prior year.
Not reported for fiscal year 2023.
Not reported for fiscal year 2023.
BPTSY Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K |
|---|---|---|---|---|---|---|
| R&D Expenses | $9.8M-43.0% | $17.2M-22.9% | $22.3M+83.4% | $12.1M+18.9% | $10.2M-6.4% | $10.9M |
| Operating Income | -$15.9Mn/m | -$24.9Mn/m | -$30.3Mn/m | -$17.1Mn/m | -$17.6Mn/m | -$15.9M |
| EBITDA | -$15.0Mn/m | -$24.4Mn/m | -$30.0Mn/m | -$16.7Mn/m | -$17.3Mn/m | -$15.6M |
| Interest Expense | $1.8M-34.1% | $2.7M-3.7% | $2.8M+52.1% | $1.9M+11.5% | $1.7M+581.9% | $246K |
| Income Tax | N/A | N/A | N/A | N/A | -$90Kn/m | -$82K |
| Net Income | -$18.8Mn/m | -$25.9Mn/m | -$35.3Mn/m | -$31.2Mn/m | -$21.3Mn/m | -$16.0M |
| EPS (Basic) | -$0.03 | -$0.15n/m | -$0.29 | -$0.53 | -$1.26n/m | -$1.20 |
| EPS (Diluted) | -$0.03 | -$0.15n/m | -$0.29 | -$0.53 | -$1.26n/m | -$1.20 |
| Diluted Shares (Avg) | 543M | 175M+47.8% | 118M | 60M | 17M | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, SG&A Expenses.
BPTSY Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K |
|---|---|---|---|---|---|---|
| Total Assets | $13.2M-43.8% | $23.5M-40.4% | $39.5M+18.6% | $33.3M+67.7% | $19.8M | N/A |
| Current Assets | $9.8M-50.7% | $19.9M-44.0% | $35.5M+20.9% | $29.4M+77.9% | $16.5M | N/A |
| Cash & Equivalents | $6.2M-47.9% | $11.8M-56.3% | $27.1M+278.7% | $7.2M+0.5% | $7.1M-56.9% | $16.5M |
| Total Liabilities | $17.5M-31.5% | $25.5M-22.3% | $32.9M+7.9% | $30.5M+4.7% | $29.1M | N/A |
| Current Liabilities | $13.7M-33.9% | $20.7M-19.8% | $25.8M-7.9% | $28.0M+22.3% | $22.9M | N/A |
| Non-Current Liabilities | $3.9M-20.8% | $4.9M-31.3% | $7.1M+186.6% | $2.5M-60.3% | $6.2M | N/A |
| Long-Term Debt | $3.6M-23.1% | $4.7M-25.2% | $6.2M+178.6% | $2.2M-63.0% | $6.1M | N/A |
| Total Equity | -$4.3Mn/m | -$2.0M-130.4% | $6.6M+134.9% | $2.8Mn/m | -$9.3M-215.4% | $8.0M |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Retained Earnings.
BPTSY Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$14.2Mn/m | -$20.3Mn/m | -$26.9Mn/m | -$11.9Mn/m | -$16.9Mn/m | -$13.8M |
| Depreciation & Amortization | $888K+71.6% | $518K+47.1% | $352K+2.8% | $342K+16.4% | $294K+13.1% | $260K |
| Investing Cash Flow | $409Kn/m | -$18K-100.1% | $13.8Mn/m | -$15.5Mn/m | -$312Kn/m | -$119K |
| Financing Cash Flow | $7.8M+18.5% | $6.6M-80.5% | $33.6M+25.3% | $26.8M+228.6% | $8.2M+5.3% | $7.8M |
Not reported in any period shown, so not listed: Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
BPTSY Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K |
|---|---|---|---|---|---|---|
| Return on Equity | N/A | N/A | -534.1%+575.8pp | -1109.9% | N/A | -199.6% |
| Return on Assets | -142.4%-32.2pp | -110.1%-20.8pp | -89.4%+4.4pp | -93.8%+13.4pp | -107.2% | N/A |
| Current Ratio | 0.72-0.2x | 0.96-0.4x | 1.38+0.3x | 1.05+0.3x | 0.72 | N/A |
| Debt-to-Equity | N/A | N/A | 0.95+0.1x | 0.80 | N/A | N/A |
| Liabilities-to-Equity | N/A | N/A | 4.98-5.9x | 10.84 | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$4.3M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.72), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| BIOPHYTIS SA BPTSY | FY2023 | N/A | -$18.8M | N/A | $18.7M | — |
| ORGENESIS INC ORGS | FY2024 | $1.0M | N/A | N/A | $3.9M | — |
| BIOXYTRAN INC BIXT | FY2025 | N/A | -$2.1M | N/A | $2.6M | — |
Where BIOPHYTIS SA Ranks
Frequently Asked Questions
Is BIOPHYTIS SA profitable?
No, BIOPHYTIS SA (BPTSY) reported a net loss of $18.8M in fiscal year 2023.
What is BIOPHYTIS SA's EBITDA?
BIOPHYTIS SA (BPTSY) had EBITDA of -$15.0M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does BIOPHYTIS SA have?
As of fiscal year 2023, BIOPHYTIS SA (BPTSY) had $6.2M in cash and equivalents against $3.6M in long-term debt.
What is BIOPHYTIS SA's operating cash flow?
BIOPHYTIS SA (BPTSY) recorded an outflow of $14.2M in operating cash flow during fiscal year 2023, representing cash used by core business activities.
What are BIOPHYTIS SA's total assets?
BIOPHYTIS SA (BPTSY) had $13.2M in total assets as of fiscal year 2023, including both current and long-term assets.
How much does BIOPHYTIS SA spend on research and development?
BIOPHYTIS SA (BPTSY) invested $9.8M in research and development during fiscal year 2023.
What is BIOPHYTIS SA's current ratio?
BIOPHYTIS SA (BPTSY) had a current ratio of 0.72 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.
What is BIOPHYTIS SA's return on assets (ROA)?
BIOPHYTIS SA (BPTSY) had a return on assets of -142.4% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
Why is BIOPHYTIS SA's debt-to-equity ratio negative or not reported?
BIOPHYTIS SA (BPTSY) has negative shareholder equity of -$4.3M as of fiscal year 2023, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is BIOPHYTIS SA's Piotroski F-Score?
BIOPHYTIS SA (BPTSY) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BIOPHYTIS SA's earnings high quality?
BIOPHYTIS SA (BPTSY) reported a net loss of $18.8M while operations used $14.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can BIOPHYTIS SA cover its interest payments?
BIOPHYTIS SA (BPTSY) reported an operating loss of $15.9M against $1.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.